Literal source text
Lobbying issues and bill citations
MED · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (H.R.7352/S.4875 119th Congress),Administration Executive Orders regarding HHS, NIH, HRSA, FDA, and CDC, Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act (119th Congress, H.R. 4445/S.4283), SUPERBUGS Act, H.R.7879, 119th Congress.
Literal federal measure citations: H.R.7352, S.4875, H.R. 4445, S.4283, H.R.7879
BUD · Budget/Appropriations
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Center for Disease Control and Prevention, National Institutes of Health, Health Resources Services Administration, Food and Drug and Administration, and global programs for various infectious diseases related issues.FY2026 State and Foreign Operations Appropriations bills FY2026 President's Budget, avian flu outbreak, Administration executive orders regarding HHS, CDC, NIH, HRSA, FDA, and USAID, FY2026 House and Senate Continuing Resolutions and related legislation, federal government shutdown-related legislation and Administrative actions, final FY2026 House and Senate Labor, Health and Human Services and State and Foreign Operations appropriations bills, FY2027 President's budget proposal, FY2027 House and Senate Labor, Health, and Human Services and State and Foreign Operations appropriations bill, FY2027 House and Senate Continuing Resolutions
HCR · Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); P, Infectious diseases and bio-preparedness health professionals loan repayment issues, ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu outbreak (generally, no specific bill), Administration executive orders regarding HHS, NIH, CDC, HRSA, FDA, and USAID FY2026, H.R. 4445/S.4283 Bio-Preparedness Workforce Pilot Program/Public Health Loan Repayment reauthorization legislation, J-1 Visa and Conrad 30 issues, H-1B Visa issues, 2026 CMS practice expense final rule, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR)(H.R. 7352/S.4875, upcoming legislation on CMS practice expense cuts, 2027 CMS Medicare Physician Fee Schedule proposed rule, H.R. 9693, Patients First Act
Literal federal measure citations: H.R. 4445, S.4283, H.R. 7352, S.4875, H.R. 9693
